All lobbying filings

MARSHALL & POPP, LLC

Lobbying for GENENTECH, INC. · Biotechnology company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 4

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
SCONRES 7
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…
HR 2882
Further Consolidated Appropriations Act, 2024

Lobbying activity 3

Pharmacy

Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 2882, FY2024 Further Consolidated Appropriations Act. Issues related to the 340B program.

Issues related to tariff and trade policy.

Trade (domestic/foreign)

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.